Are there sex differences in doxorubicin-mediated cardiotoxicity?
There are significant sex differences in doxorubicin-mediated cardiotoxicity, potentially mediated by cardiac mitochondrial dysfunction and AMPK.
Altogether, these results clearly evidence sex differences in doxorubicin toxicity. Cardiac mitochondrial dysfunction and adenosine monophosphate-activated protein kinase seem as critical sites of sex differences in cardiotoxicity as evidenced by significant statistical interactions between sex and treatment effects.
Moulin et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: